13F-HR filed by Squadron Capital Management LLC
Squadron Capital Management LLC filed this 13F-HR for the quarter ended 2026-06-30, filed 2026-08-14, with 43 holding rows worth $322,245,820.
- Accession
- 0002050709-26-000027
- Filer
- CIK 2050709
- Filed
- 2026-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2026
A holdings report, 43 entries on the cover page, a total value of $322,245,820 stated on the cover page (in dollars after the unit check, H1), rows summing to $322,245,820 with VALUE read as dollars as filed, 13F file number 028-26573. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| RELMADA THERAPEUTICS INC | 75955J402 | COMMON STOCK | 7,350,000 | $50,862,000 | dollars as filed | |
| C4 THERAPEUTICS INC | 12529R107 | COM STK | 7,200,000 | $33,624,000 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 865,000 | $33,475,500 | dollars as filed | |
| KODIAK SCIENCES INC | 50015M109 | COM | 500,000 | $19,480,000 | dollars as filed | |
| RELAY THERAPEUTICS INC COM | 75943R102 | Stock | 970,000 | $18,148,700 | dollars as filed | |
| ZENTALIS PHARMACEUTICALS INC | 98943L107 | COMMON STOCK | 3,700,000 | $17,945,000 | dollars as filed | |
| EDGEWISE THERAPEUTICS INC | 28036F105 | COM | 290,000 | $11,782,700 | dollars as filed | |
| MAZE THERAPEUTICS INC COM | 578784100 | Stock | 335,000 | $9,996,400 | dollars as filed | |
| INVENTIVA SA | 46124U107 | ADS | 2,435,000 | $9,204,300 | dollars as filed | |
| Adlai Nortye | 00704R109 | SPONSORED ADS | 764,876 | $8,796,074 | dollars as filed | |
| ENLIVEN THERAPEUTICS INC COM | 29337E102 | Stock | 160,000 | $8,120,000 | dollars as filed | |
| ARRIVENT BIOPHARMA INC | 04272N102 | COM | 183,000 | $6,357,420 | dollars as filed | call |
| PALISADE BIO INC | 696389402 | COMMON STOCK | 3,000,000 | $6,270,000 | dollars as filed | |
| BIOAGE LABS INC COM | 09077V100 | Stock | 250,000 | $6,127,500 | dollars as filed | call |
| INHIBIKASE THERAPEUTICS INC | 45719W205 | COMMON STOCK | 3,000,000 | $6,090,000 | dollars as filed | |
| ADAGENE INC | 005329107 | CMN | 1,250,000 | $5,250,000 | dollars as filed | |
| FORTE BIOSCIENCES INC | 34962G208 | COMMON STOCK | 225,000 | $4,781,250 | dollars as filed | |
| REZOLUTE INC | 76200L309 | COMMON STOCK | 900,000 | $4,680,000 | dollars as filed | call |
| Inflarx Nv | N44821101 | COM | 2,000,000 | $4,480,000 | dollars as filed | |
| ASSEMBLY BIOSCIENCES INC | 045396207 | COMMON STOCK | 160,000 | $4,396,800 | dollars as filed | |
| COMPASS PATHWAYS PLC | 20451W101 | SPONSORED ADS | 305,000 | $4,315,750 | dollars as filed | call |
| PROMIS NEUROSCIENCES INC | 74346M505 | COM SHS | 324,977 | $4,276,697 | dollars as filed | |
| CONTINEUM THERAPEUTICS INC CL A | 21217B100 | Stock | 260,000 | $4,261,400 | dollars as filed | |
| COMPASS PATHWAYS PLC | 20451W101 | SPONSORED ADS | 300,000 | $4,245,000 | dollars as filed | |
| DEFINIUM THERAPEUTICS INC | 24477V105 | COM SHS | 85,000 | $3,998,400 | dollars as filed | |
| SOL-GEL TECHNOLOGIES LTD | M8694L137 | SHS NEW | 52,000 | $3,855,280 | dollars as filed | |
| BIOAGE LABS INC COM | 09077V100 | Stock | 155,000 | $3,799,050 | dollars as filed | |
| SCYNEXIS INC | 811292309 | COM | 756,884 | $3,080,518 | dollars as filed | |
| PROQR THERAPEUTICS NV | N71542109 | SHS EURO | 1,511,496 | $2,811,383 | dollars as filed | |
| DISC MEDICINE INC COM | 254604101 | Stock | 30,000 | $2,194,200 | dollars as filed | call |
| REZOLUTE INC | 76200L309 | COMMON STOCK | 403,410 | $2,097,732 | dollars as filed | |
| LIPOCINE INC NEW | 53630X203 | COM NEW | 810,000 | $2,073,600 | dollars as filed | |
| ZENTALIS PHARMACEUTICALS INC | 98943L107 | COMMON STOCK | 426,000 | $2,066,100 | dollars as filed | call |
| C4 THERAPEUTICS INC | 12529R107 | COM STK | 400,000 | $1,868,000 | dollars as filed | call |
| ULTRAGENYX PHARMACEUTICAL IN | 90400D108 | COM | 55,000 | $1,836,450 | dollars as filed | call |
| CUE BIOPHARMA INC | 22978P205 | COM | 50,000 | $1,578,000 | dollars as filed | |
| CALCIMEDICA INC | 38942Q202 | COM NEW | 1,244,864 | $1,282,210 | dollars as filed | |
| QUINCE THERAPEUTICS INC COM | 22053A305 | Stock | 40,375 | $734,421 | dollars as filed | |
| NUVECTIS PHARMA INC | 67080T108 | COMMON STOCK | 38,700 | $711,693 | dollars as filed | call |
| PASITHEA THERAPEUTICS CORP | 70261F202 | COM NEW | 1,000,000 | $515,400 | dollars as filed | |
| INMED PHARMACEUTICALS INC | 457637700 | COM NEW | 325,000 | $503,750 | dollars as filed | |
| NEUMORA THERAPEUTICS INC. | 640979100 | COM | 100,000 | $170,000 | dollars as filed | |
| NEXTCURE INC | 65343E207 | COM NEW | 64,464 | $103,142 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0002050709-26-000027 | this filing | 2026-08-14 | acceptance time not in the bulk data set |